Download PDF
Thromb Haemost 2005; 93(01): 178-179
DOI: 10.1055/s-0037-1616162
Letters to the Editor
Schattauer GmbH

Thrombin activatable fibrinolysis inhibitor antigen could not be detected in cerebrospinal fluid

Jovan P. Antovic
1   Karolinska University Hospital & Institute, Coagulation Research, Department of Surgical Sciences, Stockholm, Sweden
,
Jan Hannerz
2   Karolinska University Hospital & Institute, Department of Neurology, Stockholm, Sweden
,
Michael Nekludov
3   Department of Neurosurgery, Stockholm, Sweden
,
Margareta Blombäck
1   Karolinska University Hospital & Institute, Coagulation Research, Department of Surgical Sciences, Stockholm, Sweden
› Author Affiliations
Further Information

Correspondence to:

Jovan P. Antovic, MD, PhD
Coagulation Research
Clinical Chemistry
L25 Karolinska University Hospital
S-171 76 Stockholm, Sweden
Phone: +46 8 517 79653   
Fax: +46 8 31 24 28   

Publication History

Received 01 June 2004

Accepted after resubmission 07 September 2004

Publication Date:
15 December 2017 (online)

 
 PDF Download Permissions and Reprints

 


#

  • References

  • 1 Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin activable fibrinolysis inhibitor. J Biol Chem 1995; 270: 1477-84.
    PubMedGoogle Scholar
  • 2 Wang W, Boffa MB, Bajzar L. et al A study of the mechanism of inhibition of fibrinolysis by activated thrombin activable fibrinolysis inhibitor. J Biol Chem 1998; 273: 27176-81.
    CrossrefPubMedGoogle Scholar
  • 3 Mosnier LO, von dem Borne PA, Meijers JC. et al Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 1998; 80: 829-35.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Mosnier LO, Buijtenhuijs P, Marx PF. et al Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets. Blood 2003; 101: 4844-6.
    CrossrefPubMedGoogle Scholar
  • 5 Antovic JP. Thrombin activatable fibrinolysis inhibitor (TAFI) a link between coagulation and fibrinolysis. Clin Lab 2003; 49: 475-86.
    PubMedGoogle Scholar
  • 6 Antovic JP, Yngen M, Östenson CG. et al Thrombin activatable fibrinolysis inhibitor (TAFI) and hemostatic changes in patients with type I diabetes mellitus with and without microvascular complications Blood Coag Fibrinolysis. 2003; 14: 551-6.
    PubMedGoogle Scholar
  • 7 Bouma BN, Marx PF, Mosnier LO. et al Thrombin- activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). Thromb Res 2001; 101: 329-54.
    CrossrefPubMedGoogle Scholar
  • 8 Wang W, Hendriks DF, Scharpe SS. Carboxy-peptidase U, a plasma carboxypeptidase with high affinity for plasminogen. J Biol Chem 1994; 269: 15937-44.
    PubMedGoogle Scholar
  • 9 Valnickova Z, Thogersen I B, Christensen S. et al Activated human plasma carboxypeptidase B is retained in the blood by binding to α 2 -macroglobulin and pregnancy zone protein. J Biol Chem 1996; 271: 12937-12943.
    CrossrefPubMedGoogle Scholar
  • 10 Fareed J, Callas DD, Hoppensteadt D. et al Tissue factor antigen levels in various biological fluids. Blood Coagul Fibrinolysis. 1995; 6 (Suppl. 01) S32-6.
    PubMedGoogle Scholar
  • 11 Suzuki M, Kudo A, Otawara Y. et al Extrinsic pathway of blood coagulation and thrombin in the cerebrospinal fluid after subarachnoid hemorrhage. Neurosurgery 1999; 44: 487-93.
    CrossrefPubMedGoogle Scholar

Correspondence to:

Jovan P. Antovic, MD, PhD
Coagulation Research
Clinical Chemistry
L25 Karolinska University Hospital
S-171 76 Stockholm, Sweden
Phone: +46 8 517 79653   
Fax: +46 8 31 24 28   

  • References

  • 1 Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin activable fibrinolysis inhibitor. J Biol Chem 1995; 270: 1477-84.
    PubMedGoogle Scholar
  • 2 Wang W, Boffa MB, Bajzar L. et al A study of the mechanism of inhibition of fibrinolysis by activated thrombin activable fibrinolysis inhibitor. J Biol Chem 1998; 273: 27176-81.
    CrossrefPubMedGoogle Scholar
  • 3 Mosnier LO, von dem Borne PA, Meijers JC. et al Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 1998; 80: 829-35.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Mosnier LO, Buijtenhuijs P, Marx PF. et al Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets. Blood 2003; 101: 4844-6.
    CrossrefPubMedGoogle Scholar
  • 5 Antovic JP. Thrombin activatable fibrinolysis inhibitor (TAFI) a link between coagulation and fibrinolysis. Clin Lab 2003; 49: 475-86.
    PubMedGoogle Scholar
  • 6 Antovic JP, Yngen M, Östenson CG. et al Thrombin activatable fibrinolysis inhibitor (TAFI) and hemostatic changes in patients with type I diabetes mellitus with and without microvascular complications Blood Coag Fibrinolysis. 2003; 14: 551-6.
    PubMedGoogle Scholar
  • 7 Bouma BN, Marx PF, Mosnier LO. et al Thrombin- activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). Thromb Res 2001; 101: 329-54.
    CrossrefPubMedGoogle Scholar
  • 8 Wang W, Hendriks DF, Scharpe SS. Carboxy-peptidase U, a plasma carboxypeptidase with high affinity for plasminogen. J Biol Chem 1994; 269: 15937-44.
    PubMedGoogle Scholar
  • 9 Valnickova Z, Thogersen I B, Christensen S. et al Activated human plasma carboxypeptidase B is retained in the blood by binding to α 2 -macroglobulin and pregnancy zone protein. J Biol Chem 1996; 271: 12937-12943.
    CrossrefPubMedGoogle Scholar
  • 10 Fareed J, Callas DD, Hoppensteadt D. et al Tissue factor antigen levels in various biological fluids. Blood Coagul Fibrinolysis. 1995; 6 (Suppl. 01) S32-6.
    PubMedGoogle Scholar
  • 11 Suzuki M, Kudo A, Otawara Y. et al Extrinsic pathway of blood coagulation and thrombin in the cerebrospinal fluid after subarachnoid hemorrhage. Neurosurgery 1999; 44: 487-93.
    CrossrefPubMedGoogle Scholar

   Permissions and Reprints